Form 4 for CYTK CYTOKINETICS INC
Accepted 2025-03-17 00:00:00 ET · period of report 2025-03-17 · accession 0001127602-25-009691 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $23.26 | +20.9K | 58.6K | +55% | +$486.1K |
| D | 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | S - Sale+OE | $45.14 | -20.9K | 37.7K | -36% | -$943.4K |
| D | 2025-03-17 | 2025-03-17 | CYTK | Callos Andrew | EVP, Chief Commercial Off | M - OptEx | $0.00 | -20.9K | 129.0K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-17 | M | A | 20,900 | $23.26 | 58,563 | D | — | — | |
| 2 | Common | Common Stock | 2025-03-17 | S | D | 20,900 | $45.14 | 37,663 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-03-17 | M | D | 20,900 | $0.00 | 129,000 | D | $23.26 · 2022-03-31 to 2031-03-31 | 20,900 Common Stock | (F1) Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer. |